Tilray's Balancing Act: Record Revenue Meets a Wall Street Rift
Published on 08/03/2026 at 18:24 | Redaktion boerse-global.de
Tilray Brands closed its fiscal year with a headline number that would make most CEOs smile — $915.5 million in revenue, an 11% jump from the prior year. Yet the market's reaction tells a more complicated story, as the cannabis-and-beverage company finds itself caught between record top-line growth and bottom-line disappointment.
The stock slipped more than 3% in pre-market trading on Monday after the company reported a fourth-quarter net loss of $0.43 per share, a figure that came in well below analyst consensus estimates. For the full year, the net loss totaled $105.2 million, even as adjusted EBITDA reached a record $61.1 million.
BrewDog's Bite Reshapes the Revenue Mix
The most significant driver of Tilray's transformation is now unmistakable: beer. The completion of the BrewDog acquisition in the fourth quarter contributed $51.1 million to quarterly sales alone. That helped push the beverages segment to $105.6 million in Q4 revenue, a 61% year-over-year increase, and $254 million for the full fiscal year.
This shift is deliberate. Management has been working to reduce the company's dependence on cannabis markets, and the strategy is showing measurable results. Beverage and pharmaceutical distribution now account for a substantial portion of growth, with international medical cannabis sales also climbing 34% over the year, buoyed by Tilray's European market leadership.
Should investors sell immediately? Or is it worth buying Tilray?
A Balance Sheet Transformed
Beyond the revenue story, the company's financial position has improved dramatically. Tilray ended the year with roughly $235 million in cash and marketable securities, while net debt has been whittled down to just $0.7 million — a hair's breadth away from a net cash position. That's a notable reversal from prior years when heavy debt loads weighed on the business.
Same Numbers, Opposite Verdicts
The August 1 analyst reactions to these results were nothing short of schizophrenic. TD Securities upgraded the stock to "Strong Buy," pointing to the successful transformation into a diversified consumer goods platform and the strengthened balance sheet. On the very same day, Wall Street Zen downgraded its rating to "Sell," citing the earnings miss and doubts about the path to sustained GAAP profitability. Jefferies, meanwhile, maintained its "Buy" rating but trimmed its price target to $19.00.
The divergence underscores just how divided the Street remains on cannabis equities in a shifting regulatory environment.
What's Next: Carlsberg and the DEA
Looking ahead, Tilray has two major catalysts in play. The company confirmed its exclusive licensing agreement with the Carlsberg Group, set to begin January 1, 2027, which will see Tilray brew, market, and distribute brands like Kronenbourg 1664 Blanc in the United States. Management expects the partnership to eventually push revenue toward an annual run rate of $1.2 billion.
On the regulatory front, investors are watching the DEA closely. With formal hearings concluded in July, the administrative judge has set August 17, 2026 as the deadline for final briefs — documents that will inform a recommendation on whether cannabis moves to the less restrictive Schedule III category. Such a change could fundamentally alter Tilray's tax burden and expansion prospects in the U.S. market.
Tilray at a turning point? This analysis reveals what investors need to know now.
For fiscal 2027, management is guiding to adjusted EBITDA between $68 million and $75 million, a target built on international medical cannabis growth and continued scaling of the North American beverage platform. The German subsidiary CC Pharma, recently recognized for innovation in medical cannabis distribution, is expected to play a central role in that push.
The stock's technical picture reflects the broader uncertainty. With an RSI of 54.5, shares sit in neutral-to-slightly-bullish territory after Friday's 7.64% jump to CAD 6.34 — a gain that puts the stock up 10.84% on the week but still down 2.76% on the month. Volatility remains elevated at 45.81%, a reminder that the market is pricing in significant uncertainty around both the DEA's decision and the Carlsberg launch.
Whether Tilray's diversification into beverages and pharma distribution can fully insulate it from the regulatory unpredictability of the global cannabis sector is the question that now divides Wall Street — and one that the coming fiscal year will put to the test.
Ad
Tilray Stock: New Analysis - 3 August
Fresh Tilray information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
